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Endometrial stromal sarcoma (ESS) formerly classiﬁed as low-grade endometrial stromal sarcoma is a rare uterine malignancy
with a good prognosis despite a tendency to recur. Primary surgical management for ESS includes total abdominal hysterectomy
and bilateral salpingo-oophorectomy. Patients with ESS have long disease-free survival rates when treated with primary surgical
therapy,butnearlyﬁftypercentofthesepatientswillrecur.WepresentthecaseofapatientwithrecurrentESSwhohadanexcellent
response to combined therapy with megestrol and leuprolide.
1.Introduction
First reported in 1908, endometrial stromal sarcoma (ESS)
is a rare uterine tumor known for its slow growth [1].
Originally known as interstitial endometrioma, endolym-
phatic stromal myosis, or low-grade endometrial stromal
sarcoma ESS is recognized by its inﬁltrating margins and
low mitotic activity [2–4]. Endometrial stromal sarcomas
represent 0.2% of all genital tract malignancies and were
previously subdivided into low- or high-grade categories
based upon their mitotic index. High-grade endometrial
stromal sarcomas are now termed poorly diﬀerentiated
or undiﬀerentiated uterine sarcomas due to its aggressive
clinical course [5–10].
Typically diagnosed postoperatively on hysterectomy
specimens, ESS has an indolent course and recurrent disease
can occur up to twenty years after diagnosis. Primary ESS is
treated surgically with a total abdominal hysterectomy and
bilateral salpingo-oophorectomy and routine lymphadenec-
tomy has not been found to improve overall survival rates [1,
3, 7, 8]. Recurrent ESS is commonly treated with progestins
like other endometrial cancers but there is no consensus
regarding optimal management [5]. ESS is hormonally
responsive and contains estrogen and progesterone receptors
[5, 11–13]. Patients with retained ovaries after a hysterec-
tomy or those who receive estrogen hormone replacement
have high recurrence rates; therefore, single agent estrogen
replacement therapy is not recommended [5]. Progestins
however are commonly used in the adjuvant setting to
treat ESS [5]. The mechanism of action of progestins is to
bind progesterone receptors and cause downregulation of
gene transcription leading to decreased endometrial gland
and stromal proliferation [11, 14]. Diminished endometrial
gland and stromal proliferation make progestins beneﬁcial
for use in the adjuvant setting and at the time of disease
recurrence. In addition, gonadotropin releasing hormone
(GnRH) agonists downregulate GnRH receptors in the
anterior pituitary leading to a hypoestrogenic state. Here, we
present the long-term followup of a patient with recurrent
endometrial stromal sarcoma treated with a progestin and
GnRH agonist with excellent results.
2.CaseReport
A 41-year-old woman gravida 2para 1 with a body mass
index of 25 presented with menorrhagia, pelvic pain, and
dysmenorrhea. Her past medical history was unremarkable.
Her past surgical history was pertinent for a bilateral2 Sarcoma
tubal ligation in 1991. After examination by her general
gynecologist, she was found to have an enlarged uterus. No
additional preoperative testing was performed. In November
1996, she underwent a total abdominal hysterectomy with
bilateral salpingo-oophorectomy. The frozen section diag-
nosis revealed a uterine stromal tumor with rare mitotic
ﬁgures. The ﬁnal pathology diagnosed an International
Federation of Gynecology and Obstetrics (FIGO) stage
IA endometrial stromal sarcoma extending to the outer
one third of the myometrium [15]. The fallopian tubes,
ovaries, and uterine serosa were negative for malignancy.
T h eu t e r u sw e i g h e d6 4 7 g r a m sa n dm e a s u r e d1 2 . 9× 12
× 7cm. Her postoperative course was uneventful and she
required no further therapy. She continued her followup
care under the management of her general gynecolo-
gist and remained without evidence of disease for two
months.
A surveillance computer tomography of the abdomen
and pelvis performed in January 1997 showed three 4-5mm
nodular densities in the right lower lobe of the lung. The
densities were too small to biopsy and no comparison ﬁlms
were available. The patient was asymptomatic and therefore
was managed conservatively. The lung densities remained
stable in size until August 1997 when one density was
found to have increased to 15 × 14mm. A lung biopsy
of the largest lesion was suspicious, but not diagnostic
for a malignancy. The enlarged lung density was thought
to clinically represent recurrent disease and the patient
was referred to a medical oncologist in her area who
recommended cytotoxic chemotherapy. The patient declined
chemotherapy and desired a second opinion.
After referral to our medical center in November 1997,
she was started on a regimen of megestrol 40mg twice
daily with monthly intramuscular injections of leuprolide
7.5mg. Complete resolution of her lung nodules occurred in
response to this regimen by January 1998. She remained on
megestrol and a 3.75mg dose of leuprolide until the date of
last followup in June 2006. Now over 10years after her initial
surgery, she remains without evidence of disease.
3. Discussion
Due to the rarity of ESS, it is diﬃcult to conduct prospective
randomized clinical trials to determine the optimal treat-
ment regimen. Treatment has been deﬁned by the experience
gained from retrospective case series and case reports. The
patient in this case was treated with megestrol and leuprolide
based on our clinical experience with this regimen. Our
experience with this combination has inﬂuenced the use
of progestins with GnRH agonists by graduates of our
department [16].
Treatment of recurrent ESS is unclear. Chu and col-
leagues published ﬁndings showing that 75% of patients
with stage I disease did not recur if treated with adjuvant
megestrol compared to 29% of similarly staged patients
who did not receive adjuvant megestrol [5]. Based on these
ﬁndings,theauthorsrecommendadjuvantmegestrol160mg
daily [5]. Several other studies have highlighted the use of
GnRH agonists, progestins, and aromatase inhibitors alone
or in combination with eﬀective therapies in the treatment
of ESS [17]. One case report published in 2004 showed good
response with single agent GnRH analogue, triptorelin, in a
patient with recurrent ESS [18]. Recurrent ESS has also been
treated with radiation, surgical reexcision, chemotherapy, or
a combination of these modalities, however, data supporting
these treatments are limited [5, 11, 19–24]. Hormonal
therapy has been studied the most in ESS. In one case series
of 13women with recurrent ESS who received hormonal
management, 46% had an objective response [21]. The type
of progestin varied in this study, but despite the type of
progestin used (megestrol, medroxyprogesterone acetate, or
hydroxyprogesterone acetate), all of the patients treated with
hormonal management had favorable outcomes, leading us
to believe that the type of progestin is not as important as the
eﬀect of progestins on this disease entity [21]. While several
other studies have documented the eﬀectiveness of other
hormonal agents such as tamoxifen, letrozole, or amniog-
lutethimide for the treatment of recurrent ESS, progestins
areinexpensive,haveafavorablesafetyproﬁle,andhavebeen
extensively studied in the treatment of uterine malignancies
[17, 20, 24–26]. Although small and retrospective in nature,
these studies illustrate the importance of the hypoestrogenic
environment provided by progestins and GnRH agonists in
the management of recurrent ESS.
In conclusion, ESS is a rare uterine malignancy with long
disease-free intervals. ESS is rarely diagnosed preoperatively
and many patients will develop disease recurrence. We have
had success in the long-term management of one patient
with recurrent ESS using megestrol and leuprolide and we
recommend its use but multicenter prospective trials are
needed to determine optimal therapy for this disease entity
in the recurrent setting.
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